Medication classes
Anti-TNF articles covering treatments such as infliximab, adalimumab, certolizumab, and golimumab in IBD care. Medication context emphasizes treatment decisions, safety, approvals, and therapy access.
Page 1 of 5 · 240 articles
If you have Crohn’s disease with perianal fistulas and are treated with infliximab, this study suggests the drug is cleared faster and trough levels are often lower after standard dosing — which may mean you need higher...
This analysis suggests delivery method for the same anti‑TNF (infliximab) may affect long‑term clinical and endoscopic outcomes in ileal-predominant Crohn’s disease. If confirmed, route of maintenance dosing could...
This study addresses a common problem in Crohn's patients on infliximab: low drug levels despite IV dosing. It suggests switching to a subcutaneous infliximab formulation can raise and stabilize trough concentrations...
People with IBD and coexisting primary sclerosing cholangitis (PSC) are at higher colorectal neoplasia risk and may respond differently to IBD medicines. This meta-analysis compiles available evidence on commonly used...
Staying on an immunomodulator with anti-TNF therapy was linked to greater long-term persistence of the biologic drug, which matters because loss of response to anti-TNF agents is a common problem in Crohn’s disease....
The study focuses on children newly diagnosed with Crohn's disease who start anti-TNF treatment and aims to identify biological and clinical markers tied to complete intestinal healing after one year; results could help...
Patients on or considering infliximab may be interested because the paper identifies a possible molecular reason some people don’t respond and tests strategies that could, in principle, improve response to infliximab.
Perianal fistulas are a common, challenging Crohn's complication that often need combined medical and surgical care; understanding local practice patterns helps patients and clinicians anticipate typical treatments and...
A blood biomarker that predicts anti-TNF response could help people with IBD and their clinicians choose the right biologic sooner, avoiding ineffective treatment. This study reports that lower baseline serum oncostatin...
Some infections (here, HIV) can closely mimic very early onset IBD. Recognizing progressive lymphopenia or unusual infections can change diagnosis and treatment, which matters because immunosuppression can worsen...
For people hospitalized with acute severe UC, the findings suggest that measuring early infliximab pharmacokinetics could help personalize rescue therapy and potentially reduce colectomy risk by identifying who may need...
Based on the title and source metadata, this appears to be an opinion or commentary related to Ulcerative colitis, Inflammatory bowel disease, and Infliximab. The original article is from Translational gastroenterology...
Predicting early need for infliximab could help identify children with Crohn’s disease who may benefit from earlier biologic therapy instead of prolonged conventional treatment. A reliable prediction tool may shorten...
Many people with Crohn’s disease or ulcerative colitis use biologic drugs; new clinical and real-world data about a subcutaneous infliximab option could affect treatment choice, switching decisions, and practical use in...
This analysis suggests a subcutaneous formulation of infliximab may lead to better clinical and endoscopic outcomes than intravenous infliximab for ileal-involved Crohn’s disease, which could affect treatment choices and...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Infliximab. The original article is from Inflammatory Bowel Diseases.
Patients on biologic therapy often have drug levels and antidrug antibodies measured to guide care. This study suggests prior biologic history, disease type (UC vs CD) and which biologic is currently used may affect...
The study explores whether blood redox biomarkers relate to short- and long-term response to infliximab or vedolizumab, which could help predict who benefits from these biologics. It also suggests a link between...
The study suggests that using infliximab as first-line therapy (rather than IV corticosteroids) may produce more durable remission and reduce long-term colectomy risk in moderate-to-severe ulcerative colitis.
Perianal fistulizing Crohn's disease causes major quality-of-life problems and is often hard to treat. This trial tests risankizumab in people who did not respond to or could not tolerate other standard therapies, and it...
This OLE study follows patients who lost response to ustekinumab every-8-week dosing and evaluates whether increasing to every-4-week dosing maintains efficacy and safety long-term. That question is directly relevant to...
Patients and clinicians may see continued availability and promotion of Skyrizi and Rinvoq across IBD indications, which can affect prescribing options and market competition. Sales growth and approvals also influence...
Conference analyses describe how subcutaneous infliximab performs after stopping IV treatment and when compared with IV infliximab for ileal/ileocolonic Crohn's — information that could affect treatment decisions for...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Infliximab, and Anti-TNF. The original article is from Frontiers in pediatrics.
The study suggests pulmonary nodules are more common in people with Crohn’s disease and that age and certain medications (not disease phenotype) may better predict nodule burden — information that could influence how...
Modeled cost savings and fewer hospital visits could affect access to infliximab for people with Crohn’s disease and other autoimmune conditions in Jordan, potentially increasing the number of patients who can be treated...
Adherence affects how well advanced IBD treatments work. Knowing which drug forms and patient factors link to missed doses can help patients and clinicians plan support strategies.
This review directly addresses whether switching from originator infliximab to a biosimilar affects disease control or safety in children with IBD — a common practical concern for families and clinicians. Its pooled data...
The analysis suggests that some biologic and small-molecule therapies work differently depending on whether Crohn's disease affects the ileum, colon, or both — information that could help tailor long-term treatment...
A rapidly growing abdominal mass or unexplained systemic decline in someone with Crohn's disease may represent a rare malignancy (plasmablastic neoplasm) rather than infection or a disease flare; prompt biopsy is...
Families and clinicians deciding on a first biologic for a child with ulcerative colitis need to know which drugs have pediatric-specific evidence. This review shows infliximab has the strongest pediatric data, while...
If local norepinephrine promotes neutrophil‑driven inflammation in UC, that could help explain disease progression in some patients and point to biomarkers (ADRB2‑rich neutrophils) that might predict response to anti‑TNF...
Pulmonary nodules appear more frequently in people with Crohn’s disease and have distinct patterns over time. Knowing which factors predict nodule burden can help clinicians prioritize monitoring and interpret chest...
Perianal fistulas cause significant morbidity and often need both medical and surgical treatments. Newer drug options and updated guideline support earlier use of advanced therapies, which may improve healing and reduce...
Perianal fistulizing Crohn's often causes significant symptoms and requires both medical and surgical approaches. Newer biologics and JAK inhibitors expand treatment options and guidelines increasingly support earlier...
This study gives real-world comparative data on two biologic options (vedolizumab vs anti-TNFα) used early in the treatment course for Crohn’s disease, which may help patients and clinicians weigh effectiveness and...
A subcutaneous option for infliximab could simplify maintenance therapy, reduce infusion visits, and change how drug levels and accompanying immunomodulators are managed — issues many people with IBD and their clinicians...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Infliximab. The original article is from Inflammatory Bowel Diseases.
Predicting who will relapse after stopping anti-TNF drugs could help avoid unnecessary flares or unnecessary ongoing treatment. A biopsy-based transcriptomic test could be a useful decision tool if validated.
Launches of adalimumab and ustekinumab could expand local access to two widely used biologic treatments for Crohn’s disease and ulcerative colitis. Wider availability may affect treatment options and logistics for people...
For people with Crohn’s disease, this study suggests that biologic drugs reduce inflammation in both proximal and distal small bowel to a similar degree, as measured by capsule endoscopy.
For people with UC who do not respond to tacrolimus, adding infliximab may induce remission and reduce the short-term need for colectomy. The findings point to a potential rescue strategy and an option to transition to...
People with IBD on biologic therapies may benefit from accurate drug-level testing to guide treatment decisions.
Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Infliximab, and Anti-TNF. The original article is from Polish archives of internal medicine.
Cure8 found this source from drugstorenews.com, but the page could not be read reliably yet. It is tagged for Adalimumab, Biosimilars, and Anti-TNF. Open the original article for the full details.
Bright, round objects on stomach CT scans can be mistaken for retained pills or bleeding. For people with Crohn's disease who commonly receive CT enterography and may have bile reflux or duodenal narrowing, this report...
A single‑patient report suggests guselkumab (IL‑23 inhibitor) may control both refractory pyoderma gangrenosum and coexisting Crohn disease when several prior treatments failed.
This registry will gather real-world safety and effectiveness data on infliximab in Chinese children with moderate-to-severe Crohn's disease, which can help clinicians and families understand how the drug performs...
